© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
May 27, 2022
Fear of discrimination has downstream effects on health care.
May 19, 2022
TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in variant histology bladder cancer.
May 16, 2022
“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
May 02, 2022
The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.
April 12, 2022
High genomic loss of heterozygosity may serve as a predictive marker for response to talazoparib in patients with metastatic castration-resistant prostate cancer.
April 11, 2022
Results shared during the 2022 AACR Annual Meeting suggested that genetic adjustment of prostate-specific antigen may reduce overdiagnosis of prostate cancer, de-escalate invasive testing, and improve the detection of aggressive disease.
NGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
April 07, 2022
The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.
March 17, 2022
“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.
March 14, 2022
“I think that it's very clear that this test is independently prognostic,” says Daniel E. Spratt, MD.